(Lung Cancer) Pembrolizumab + Docetaxel: What the Study Reported
(Lung Cancer) Pembrolizumab + Docetaxel: What the Study Reported
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) Pembrolizumab + Docetaxel: What the Study Reported
- May 18, 2020
- 2 min read
On April 9, 2020, Oscar Arrieta published in the medical journal JAMA Oncology the efficacy and safety results of anti-PD-1 antibody anti-PD-1 antibody + Docetaxel for previously treated advanced non-small cell lung cancer patients in the PROLUNG Phase II clinical trial.
The PROLUNG Phase II clinical trial randomized previously treated advanced non-small cell lung cancer patients in a 1:1 ratio into the following two groups, with the primary endpoint being objective response rate and secondary endpoints including progression-free survival, overall survival, and safety:
-
anti-PD-1 antibody group (three-week cycles for up to six cycles, anti-PD-1 antibody 200 mg + Docetaxel 75 mg/m2, followed by anti-PD-1 antibody monotherapy as maintenance therapy)
-
Docetaxel group (Docetaxel 75 mg/m2)
The primary rationale for this trial was that for advanced non-small cell lung cancer patients with disease progression after platinum-based chemotherapy, there were few clinical trials evaluating immune checkpoint inhibitors + chemotherapy as initial combination therapy. Based on this background, the trial was initiated.
The trial results showed that the primary endpoint objective response rate was 42.5% for the anti-PD-1 antibody group and 15.8% for the Docetaxel group. Objective response rates for patients with EGFR mutations were 58.3% for the anti-PD-1 antibody group and 23.1% for the Docetaxel group. Objective response rates for patients without EGFR mutations were 35.7% for the anti-PD-1 antibody group and 12.0% for the Docetaxel group.
Secondary endpoint progression-free survival was 9.5 months for the anti-PD-1 antibody group and 3.9 months for the Docetaxel group. For patients with EGFR mutations, it was 6.8 months for the anti-PD-1 antibody group and 3.5 months for the Docetaxel group. For patients without EGFR mutations, it was 9.5 months for the anti-PD-1 antibody group and 4.1 months for the Docetaxel group.
Based on the PROLUNG clinical trial results, Oscar Arrieta concluded that for previously treated advanced non-small cell lung cancer patients, anti-PD-1 antibody anti-PD-1 antibody + Docetaxel showed improved objective response rate and progression-free survival compared to Docetaxel monotherapy.
[Disclaimer] The clinical trial data and pharmaceutical information translated by "Medical Supporter" from overseas trials are not intended to encourage participation in clinical trials or the use of new drugs. The translated materials are for reference only and are not prescribing guidelines. Please discuss with your healthcare provider, and refer to the original text at the bottom of the article for accurate content.
Source: Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (JAMA Oncol. 2020 Apr 9. doi: 10.1001/jamaoncol.2020.0409.)
#LungCancer #anti-PD-1 antibody
-
Immunotherapy
-
Investigational Drugs
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is the Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.